Will This Potential Approval Be a Winner for Sanofi's Shareholders?
Last month, Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) immunology mega-blockbuster, known as Dupixent, received some good news. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, recommending approval of the drug to treat patients with a rare skin condition called prurigo nodularis.
With approval potentially only months away, it's worth assessing the sales potential of this new indication for Dupixent. For that purpose, let's dive into the drug's efficacy from clinical trials and the size of the prurigo nodularis market in the European Union.
Prurigo nodularis is a chronic, inflammatory skin disease that causes extreme itch among patients. The disease often includes thick patches of skin called nodules that result in burning, stinging, and tingling sensations.
Source Fool.com
